



ELSEVIER



BASIC SCIENCE

Nanomedicine: Nanotechnology, Biology, and Medicine
14 (2018) 1267–1277

Original Article

nanomedjournal.com

Polymersome nanoparticles for delivery of Wnt-activating small molecules

Edoardo Scarpa, PhD^{a,b}, Agnieszka A Janeczek, PhD^a, Alethia Hailes, BSc(Hons)^{a,b},
Maria C de Andrés, PhD^a, Antonio De Grazia, MSc(Hons)^a, Richard OC Oreffo, DSc^{a,b},
Tracey A Newman, PhD^{b,d,*}, Nicholas D Evans, PhD^{a,b,c,*}

^aCentre for Human Development, Stem Cells and Regeneration, Bone and Joint Research Group, University of Southampton Faculty of Medicine, Southampton, United Kingdom

^bInstitute for Life Sciences, Centre for Biological Sciences, B85, University Road, University of Southampton, Southampton, United Kingdom

^cBioengineering Sciences Group, Faculty of Engineering and the Environment, University of Southampton, Highfield, Southampton, United Kingdom

^dClinical and Experimental Sciences, Medicine, University of Southampton, Southampton, United Kingdom

Received 30 August 2017; accepted 24 February 2018

Abstract

Spatiotemporal control of drug delivery is important for a number of medical applications and may be achieved using polymersome nanoparticles (PMs). Wnt signalling is a molecular pathway activated in various physiological processes, including bone repair, that requires precise control of activation. Here, we hypothesise that PMs can be stably loaded with a small molecule Wnt agonist, 6-bromoindirubin-3'-oxime (BIO), and activate Wnt signalling promoting the osteogenic differentiation in human primary bone marrow stromal cells (BMSCs). We showed that BIO-PMs induced a 40% increase in Wnt signaling activation in reporter cell lines without cytotoxicity induced by free BIO. BMSCs incubated with BIO-PMs showed a significant up-regulation of the Wnt target gene *AXIN2* (14 ± 4 fold increase, $P < 0.001$) and a prolonged activation of the osteogenic gene *RUNX2*. We conclude that BIO-PMs could represent an innovative approach for the controlled activation of Wnt signaling for promoting bone regeneration after fracture.

© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Key words: Polymersomes; Wnt; Drug delivery

Controlled, spatiotemporal delivery of therapeutic molecules is a major goal in medicine that may be achieved by the use of nanosized carriers.¹ Polymersomes (PMs) are an attractive candidate delivery agent. They are vesicles formed by the self-assembly of amphiphilic copolymers in aqueous solutions.² PMs possess a hydrophilic core and an amphiphilic shell which can accommodate a variety of hydrophilic and hydrophobic molecules and drugs at high concentration. PMs can be synthesised from a wide range of biodegradable polymers, and may be engineered to release payloads in response to

environmental stimuli.^{3–5} Furthermore, the outer surface of PMs can be composed entirely of polyethylene glycol (PEG) in order to prolong their *in vivo* circulation time,⁶ and/or can be coupled with cell or tissue targeting motifs.^{7,8} To date, the majority of research on PMs as drug delivery vehicles has focused on cancer chemotherapy, where there is a need to deliver high concentrations of toxic and often highly water-insoluble drugs selectively to tumours.⁹ Various studies have shown that PMs can incorporate a wide variety of chemotherapeutic small molecules.^{10,11} Very recently PMs have been shown to increase

The authors state that they have no conflict of interest.

We gratefully acknowledge support from the Medical Research Council, United Kingdom, (Grant number MR/J004103/1), Wessex Medical Research, UoS Research Management Committee, Nanoear FP6 (FP-6 NMP4-CT-2006), a Vice Chancellor's award from Malaya University, Malaysia, awarded to TAN, and the Institute for Life Sciences, Southampton, U.K.

*Corresponding authors at: Institute for Life Sciences, Centre for Biological Sciences, B85, University Road, University of Southampton, Southampton, United Kingdom.

E-mail addresses: tan@soton.ac.uk (T.A. Newman), n.d.evans@soton.ac.uk (N.D. Evans).

<https://doi.org/10.1016/j.nano.2018.02.014>

1549-9634/© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

the therapeutic index of paclitaxel in a model of gastric cancer in comparison to the albumin-bound formulation of paclitaxel currently commercialized as Abraxane®.¹² Building on these encouraging results, there is emerging data supporting the utility of PMs as drug delivery vehicles beyond oncology.^{13,14} These studies open up the possibility of applications of PMs in disease conditions where control over intracellular delivery, pharmacokinetic profile, and spatiotemporal delivery are fundamentally important.

We are investigating the notion that PMs might be exploited for the spatiotemporally-controlled delivery of therapeutic molecules to bone injury sites to promote fracture repair. Bone fracture is a highly regulated, reparative process that involves a sequence of distinct but overlapping physiological processes.¹⁵ Uncomplicated fractures generally heal well, but in some circumstances - for example in high-energy fractures, or when there is significant underlying pathology - fracture healing is delayed or may not occur. Delayed or non-union fractures are a significant clinical burden^{24,25} and new therapies are urgently required, but there are currently no clinically-approved drugs available for systemic administration that promote fracture healing.¹⁷

The canonical (β -catenin-dependent) Wnt signalling pathway is a highly conserved molecular pathway that in bone tissue plays a fundamental role controlling bone homeostasis and repair,¹⁵ and it is an attractive drug target in this context. Several Wnt-targeting drugs have shown exceptional promise in increasing bone mass in patients with osteoporosis.¹⁸ However, there is a paucity of evidence to suggest that these therapeutics could be successful in fracture healing in humans. This may stem from the pleiotropy of Wnt signalling – elevated Wnt signalling can exert strongly stimulatory effects on bone fracture, but can also inhibit bone healing if activation is not timed appropriately.^{19,20} Furthermore, we recently demonstrated that Wnt activation in bone stem cells can both promote and inhibit osteogenic differentiation in a similar manner.²¹ For this reason, it is likely that if Wnt signalling is to be exploited in fracture healing, its activation must be spatially and temporally regulated.

Nanodelivery provides a potentially attractive answer to this challenge. Previous work has indicated that Wnt3A protein can be stably associated with nanosized liposomes and improve bone healing,²⁰ osseointegration²² and stem cell activation.²³ The use of recombinant proteins as therapeutic agents however has several disadvantages, including expense of production and poor stability during storage or following administration.²⁴ An alternative approach is to exploit stable, inexpensive, synthetic small molecules that activate Wnt signalling. Examples are AZD 2858 and AR-28, small molecules that have been shown to enhance bone mass^{25,26} and augment fracture repair²⁷ in rats and mice, or 6-bromoindirubin-3'-oxime (BIO), the administration of which resulted in a significant increase in bone trabecular number and thickness,²⁸ as well as increased dentin mineralization following injury in healthy mice.²⁹ Nonetheless, the clinical application of many of these molecules including BIO is limited by poor solubility, bioavailability and cytotoxicity at high concentrations.³⁰

In this study, we hypothesized that encapsulation of BIO in PMs would allow the activation of the Wnt pathway in a

controlled manner while reducing the cytotoxicity associated with the delivery of high concentrations of BIO. We produced PMs using polyethylene glycol- polycaprolactone (PEG-PCL) block copolymer. Both PEG and PCL polymers are approved for the use in clinic, therefore enabling rapid translational of research findings. We provide evidence of encapsulation and retention of a BIO in PMs and for a cell-protective function promoted by drug encapsulation within PMs. Finally, we demonstrate BIO loaded-PMs promote osteogenic differentiation in human primary cells, findings that highlight the potential of this system in regenerative medicine.

Methods

Extended materials and methods can be found in the Supplementary Data.

Results

6-Bromoindirubin 3'-oxime (BIO) can be stably loaded in PCL-PEG polymersomes

We first loaded PCL-PEG PMs with 6-bromoindirubin-3'-oxime (BIO), an ATP-competitive inhibitor of glycogen-synthase-kinase-3 β (GSK-3 β) by dissolving BIO either in the organic solvent fraction or in the aqueous PBS (Figure 1).

To differentiate these techniques, we termed these resulting PM preparations 'DMF-dissolved' or 'PBS-dissolved' respectively.

PBS- and DMF-dissolved PMs (Figure 2, A) displayed uniform size distributions of ~ 65 nm \pm 18 nm and similar final concentrations of 1.5×10^{13} PMs ml⁻¹ as measured by nanoparticle tracking analysis (NTA) (Figure 2, B). These sizes were in good agreement with the hydrodynamic diameter measured by dynamic light scattering (DLS) (~ 62 nm \pm 22 nm) (Figure 2, C). Unloaded PMs were slightly smaller than BIO-loaded PMs (~ 57 nm vs. ~ 62 nm, Figure 2, C and Table 1), but this difference was not significant ($P = 0.70$). Neither were there any significant differences in the charge of PMs, as measured by ζ -potential (Table 1).

On storage of PMs for up to 14 days, minor (<10%) changes in size were observed for empty or DMF-dissolved PMs (Figure 2, D). In contrast, core-loaded PMs were unstable, with an increase in size from 65 nm to 210 nm between 7 and 14 days and concurrent increase in the polydispersity index (PDI) (from 0.19 to 0.31, Figure 2, D).

Next, we quantified the amount of BIO loaded in the two preparations following synthesis and purification using absorption spectroscopy. BIO has absorbance peaks at 535 and 580 nm where there is little interference from Rayleigh scattering from PMs (Supplementary Figure 1, A). We used absorbance of BIO at 535 nm to determine a standard curve for BIO (Supplementary Figure 1, B). Following purification, comparable concentrations of BIO were measured in bulk suspensions (15×10^{12} PMs ml⁻¹) of core-loaded (187 ± 36 μ M) and DMF-dissolved PMs (198 ± 32 μ M). Based on these data we estimated an encapsulation efficiency of $\sim 90\%$ for both formulations. Finally, we measured the stability of the




Figure 1. Schematic summary. (A) Cartoon depicting the structure of a polymersome (PM) indicating the aqueous core and the hydrophobic shell. (B) Schematic representation of the methodology used to load BIO in PMs after dissolving it into DMF or PBS. (C) Image summarizing the cell types and readout methodologies used. BIO: 6-bromoindirubin 3'-oxime; DMF: dimethylformamide; PBS: phosphate buffered saline; PEG-PCL: Polyethylene glycol-polycaprolactone; PM: polymersome.

incorporation of BIO in the stable, DMF-dissolved PMs under continuous dialysis sink conditions (Figure 2, E). BIO association with PMs was stable for 1–2 days with negligible release, after which release occurred steadily with $\sim 10 \pm 1\%$ lost at day 3, and $56.68 \pm 2.5\%$ of BIO lost between day 3 and 5. After this period, the residual BIO was slowly but constantly released from the PMs, as demonstrated by the presence of $22.3 \pm 4.2\%$ and $12.3 \pm 6.7\%$ of the original concentration loaded still present after 10 and 14 days, respectively (Figure 2, E). In summary, these data illustrate that the Wnt pathway agonist BIO can be loaded in PCL-PEG PMs at high concentrations for time periods of up to 48 hours.

BIO-loaded PMs are taken up by Wnt reporter cells and bone marrow stromal cells (BMSCs)

Then we investigated the internalization of PMs in Wnt-responsive and functionally relevant cells.³¹ This relies on the incorporation within PMs of self-quenched high concentration of fluorescein, which then becomes detectable following release from nanoparticles (Figure 3, A).

After 24 hours of incubation with PMs, both 3T3 Leading Light[®] Wnt reporter cells and bone marrow stromal cells (BMSCs) were positive for fluorescein as measured by microscopy, indicating internalization of PMs and release of payload (Figure 3, B). To investigate the kinetics of PMs uptake by these two cell types we used flow cytometry. Figure 3, C and D show that within 1 hour of incubation 100% of 3T3 cells are positive for fluorescein, compared to $91\% \pm 11\%$ of BMSCs. 100% positivity of BMSCs

for fluorescein was not reached until 3 hours (Figure 3, C and D). We observed differences in the relative mean fluorescence intensity of each cell line, indicating differential PM uptake between cell types (Figure 3, E). There was also a difference in the kinetics of uptake between cells. The time at which half-maximal fluorescence intensity ($\tau_{1/2}$) was reached was ~ 1 hour for BMSCs compared to ~ 2.5 hours for 3 T3 cells. Inclusion of BIO in fluorescein-containing PMs did not affect the total number of cells that became positive for fluorescein, but resulted in a decrease in the mean cellular fluorescence of $10 \pm 3\%$ and $21 \pm 2\%$ for reporter cells and BMSCs, respectively (Supplementary Figure 2). Together this data indicate that PMs are rapidly taken up by 3T3 Wnt reporter cells and human BMSCs, that the payload is released intracellularly, and that inclusion of BIO has a minor effect on the degree of uptake.

BIO-PMs induce Wnt signalling in a dose-dependent manner

To determine whether PM-delivered BIO was able to induce Wnt signalling we incubated reporter cells with PBS-, DMF-dissolved PMs or free BIO for 24 hours and measured the level of Wnt activation by luciferase production (Figure 4, A). Both PM preparations induced Wnt signalling activation. Compared to free BIO, which has a maximum activation at a concentration of $\sim 5 \mu\text{M}$, DMF-dissolved PMs induced a maximum response at a factor of 0.46 ± 0.03 of the readout measured using $5 \mu\text{M}$ free BIO, while PBS-dissolved PMs induced a maximal response at a factor of 0.15 ± 0.03 of free BIO. This was despite PBS- and DMF-dissolved PMs contained comparable concentration of BIO (Figure 4, B).




Figure 2. Characterisation of polymersomes loaded with BIO. (A) Cartoon depicting the three different polymersome (PM) preparations (B) Concentration and size measurement histogram from NTA of PBS- and DMF-dissolved PMs. (C) DLS histogram showing the hydrodynamic distribution in diameter of PBS- and DMF-dissolved PMs, and empty PMs. (D) Graph showing the size stability in solution of PMs over the course of 14 days. (E) Plot depicting the release profile of DMF-dissolved PMs over 20 days. Data presented as mean \pm SD ($n = 3$).

We also confirmed the stability of the association between BIO and PMs. We ultracentrifuged DMF-dissolved PM suspensions to separate the PMs from supernatant and demonstrated that the activity of the preparation (*i.e.* the ability to induce the activation of the Wnt pathway in reporter cells) was retained in the pellet fraction consisting of PMs (~90% of the total activity measured) (Figure 4, C). As suggested by data in Figure 2, E, we confirmed that the association of BIO with PMs was stable for up to 36 hours. Continuous dialysis under sink conditions did not diminish the activity of the PM-BIO

pellet, with no activity lost to the supernatant or through the dialysis tubing (Figure 4, D).

PM encapsulation protects cells from BIO-induced toxicity but retains Wnt signalling activity

Although being an established inhibitor of GSK-3 β ,³⁴ BIO is relatively membrane impermeable and its IC₅₀ is ~5 nM for GSK-3 β . However, extracellular concentrations of 500–1000 \times

Table 1
Polymersome (PM) preparations over time.

Day	PMs								
	Empty-PMs			Core-BIO loaded PMs			Shell-BIO loaded PMs		
	DH	PdI	ζ -potential	DH	PdI	ζ -potential	DH	PdI	ζ -potential
1	56 ± 22	0.11	-5 ± 2.1	62 ± 25	0.19	-4 ± 2.7	63 ± 26	0.11	-6 ± 0.96
7	59 ± 22	0.11		65 ± 27	0.19		60 ± 21	0.14	
14	60 ± 21	0.11		210 ± 50	0.31		62 ± 22	0.15	

Summary of size, polydispersity index (PI) and ζ -potential of PBS- and DMF-dissolved PMs and empty-PMs over 21 days. Data presented as mean ± SD ($n = 3$). PDI: polydispersity index; PM: polymersome.




Figure 3. Cellular uptake of fluorescein-loaded polymersomes (PMs). (A) Cartoon depicting the methodology used to assess cellular uptake of PMs using fluorescein. When carrying a payload of fluorescein above the quenching concentration the PM is non-fluorescent. Upon cellular internalization payload release can be visualized as the fluorescein disperses and falls below the quenching concentration. (B) Fluorescence imaging showing intracellular release of fluorescein in 3 T3 Wnt reporter cells and human bone marrow stromal cells (BMSCs) incubated with fluorescein-PMs for 1 hour. (C) Representative flow cytometry histogram of 3 T3 Wnt reporter cells and human BMSCs incubated for 1, 3, 6 or 24 hours with fluorescein-PMs. Both graphs show the progressive increase in fluorescence intensity of cells treated with fluorescein-PMs compared to 99% of the control untreated cells (grey). Dotted lines indicate the markers set to discriminate between positive and negative cells. (D) Graph depicting the progressive increase in the percentage of cells positive for fluorescein over-time. (E) Graph depicting the progressive increase in the relative fluorescence intensity over-time. Data presented as mean ± SD ($n = 3$).

greater ($\sim 2 \mu\text{M}$) are required to induce half maximal response in the Wnt-signalling pathway (Figure 5, A).³⁵ In parallel, BIO is known to cause cytotoxicity by unknown mechanisms,³⁵ probably through binding to other intracellular kinases such as CDKs, JAK–STAT.^{36–38} We hypothesized that delivery of BIO using PMs would reduce these non-specific effects through a more controlled delivery.

To investigate this, we incubated 3T3 reporter cells with increasing concentrations of either DMF-dissolved PMs (hereafter referred as to BIO-PMs) or free BIO and compared their effects on activity and cell-induced toxicity. Free BIO promoted Wnt signalling activity in a dose-dependent manner with a maximal response at a concentration of $5 \mu\text{M}$, and a progressive decline at higher concentrations. The maximal activation of Wnt

signalling using BIO-PMs was reached at a concentration of $15 \times 10^{11} \text{ PMs ml}^{-1}$, corresponding to $46 \pm 3\%$ of the maximal activity measured using $5 \mu\text{M}$ BIO. Similar to free BIO, at concentrations higher than $15 \times 10^{11} \text{ PMs ml}^{-1}$, BIO-PMs also resulted in a decrease in reporter cell activity (Figure 5, A), albeit less markedly than with free BIO. We found a dose-dependent decrease in cell viability in response to free BIO ($57 \pm 10\%$ of cell survival at an extracellular concentration of $5 \mu\text{M}$), but no decrease in cell viability in response to BIO-PMs, even at concentrations that induced a decline in pathway activation (Figure 5, B and C). This suggests that in contrast to free BIO, BIO-PMs at any extracellular concentration tested do not have cytotoxic effect on cells. The decreased pathway activation at high PM concentrations must therefore occur by non-cytotoxic




Figure 4. Stable encapsulation of BIO within polymersomes (PMs). (A) Overview of the luciferase assay used to assess activity of PMs loaded with BIO. After incubation with either free BIO or loaded PMs, the small molecule inhibits GSK-3 β in the cytosol allowing for the accumulation of β -catenin and, following translocation to the nucleus, activation of the Wnt pathway. As a consequence of the activation of the pathway, the luciferase enzyme is synthesised. (B) Bar chart showing the fold increase in Wnt signalling activation of 3 T3 luciferase reporter cells incubated for 24 hours with 15×10^{11} PMs ml $^{-1}$ of PBS-, DMF-dissolved or empty PMs, or 5 μM BIO ($n = 9$). (C) Bar chart showing the level of activity of DMF-dissolved PMs and either pellet or supernatant following ultracentrifugation ($n = 4$). (D) Bar chart showing the unaltered relative activity of 3 T3 luciferase reporter cells incubated for 24 hours with BIO-PMs dialyzed for either 12, 24 or 36 hours ($n = 5$). In B, C & D values are normalized against untreated cells, and are expressed as relative activation of cells treated with 5 μM BIO for 24 hours. All the data is presented as mean \pm SD, one-way ANOVA, with Sidak's post-hoc correction, **** $p < 0.0001$. APC: adenomatous polyposis coli; BIO: 6-bromoindirubin 3'-oxime; DVL: dishevelled; GSK-3 β : glycogen synthase kinase-3 β ; LEF: lymphoid enhancer factor; TCF: T-cell factor; β -cat: β -catenin.

mechanisms. Notably, we did not find any effect of empty PMs on free-BIO induced Wnt pathway activation, nor of increases in PM PBS buffer solution (Supplementary Figure 3).

It is likely that the protection of cytotoxicity conferred by encapsulation of BIO may result from an uptake route that provides more specific delivery to its intended target. To investigate this, we measured the temporal activation of Wnt signalling in the reporter cell line by performing a pulse chase experiment, where cells were exposed to either PMs or free BIO for fixed periods of times, before wash-out and subsequent assessment of pathway activation at 24 hours (Figure 5, E). In order to compare free BIO and BIO-PMs, extracellular concentrations were selected (i.e. final concentrations in the cellular media) that elicit an equivalent activation of the Wnt signalling pathway in a 24 hour activation experiment. These concentrations were calculated from the experiments reported in Figure 5, A and are 2 μM and 15×10^{11} mL $^{-1}$ for free BIO and BIO-PMs, respectively. As shown in Figure 5, F, the activity measured was greater for free BIO than for BIO-PMs for short exposure times (1–6 hours), but was similar at time periods of <12 hours. Supporting this, at 48 hours post incubation, BIO-PMs induced a significantly higher level of Wnt signalling activation than 2 μM free BIO (Supplementary Figure 4,

$p < 0.05$). These results suggest that free BIO enters cells more quickly than BIO-PM and that BIO delivered by PMs requires a longer period of time to accumulate and activate signalling. Together these data indicate that BIO-PMs activate Wnt signalling, are not cytotoxic, and allow for a time-controlled delivery of high concentrations of payload, which would be cytotoxic if administered in a 'free' form.

Application of BIO-PMs to achieve osteogenic priming of human multipotent stromal cells

Activation of Wnt signalling is crucial in many repair processes, including bone regeneration following injury. Multipotent BMSCs contribute to bone repair and their differentiation to osteoblasts is known to be modulated by canonical Wnt signalling^{21,23,39}; therefore, they represent a good target for assessing the biological activity of PM-mediated Wnt activation (Figure 6, A).

Incubation of BMSCs with BIO-PMs resulted in a significant increase in the expression of the Wnt target gene *AXIN2* at 24 hours (12 ± 6 fold increase, $p < 0.001$, for 6×10^{11} BIO-PMs mL $^{-1}$ and 9 ± 3 fold increase, $p < 0.05$, 15×10^{11} BIO-PMs mL $^{-1}$). Similarly, 2 μM free BIO also




Figure 5. Comparison of BIO-Polymersomes (PMs) vs. free BIO activity, induced cytotoxicity and kinetics. (A) Dot plot graph depicting the activity of 3T3 luciferase reporter cells incubated for 24 hours with increasing concentrations of either BIO-PMs (black) or free BIO (red). ($n = 3$). (B) Dot plot graph depicting the progressive reduction in viability of 3 T3 luciferase reporter cells incubated for 24 hours with increasing concentrations of free BIO (red), whilst cells exposed to BIO-PMs (black) were unaffected ($n = 3$). (C) Representative pictures of 3 T3 luciferase reporter cells treated with 15×10^{11} BIO-PMs ml⁻¹. (D) Representative pictures of 3 T3 luciferase reporter cells treated with 2 μM BIO. (E) Schematic representation of the time points investigated during the pulse-chase experiments. (F) Dot plot graph of 3 T3 reporter cells activity after incubation with either BIO-PMs (15×10^{11} BIO-PMs ml⁻¹, black) or 2 μM BIO (red) for increasing time periods (1, 2, 3, 6, 12 or 24 hours), ($n = 3$). All the data is presented as mean \pm SD. Values are normalized against untreated cells, and are expressed as relative activation of cells treated with 5 μM BIO for 24 hours.

promoted *AXIN2* expression at 24 hours (14 ± 4 fold increase, $p < 0.001$). However, BIO-PMs promoted a sustained activation of Wnt signalling compared to free BIO ($p < 0.0001$), before declining to baseline levels or lower after 4 days (Figure 6, B). These data indicate that BIO-PMS are internalized by BMSCs and that BIO-PMS promote a prolonged activation of the Wnt signalling pathway.

Next, we investigated whether the activation of Wnt induced by BIO-PMs would also promote osteogenic differentiation of BMSCs. As shown in Figure 6, C, the osteogenic ‘master gene’ *RUNX2*, was markedly up-regulated following 24 hour treatment with BIO-PMs (more than 1.5 fold increase compared to control), and significantly increased after incubation with 2 μM BIO (2.5 ± 0.5 fold increase compared to control, $p < 0.05$). Importantly, incubation of BMSCs




Figure 6. BIO-polymersomes promote osteogenic commitment of human bone marrow stromal cells (BMSCs). (A) Cartoon depicting the genes investigated. (B) Relative expression of *AXIN2* in BMSCs incubated for 24, 48 or 96 hours with either BIO-PMs (6×10^{11} or 15×10^{11} BIO PMs ml⁻¹) or 2 μM BIO, ($n = 3$). (C) mRNA expression of *RUNX2* in BMSCs incubated for 24 or 96 hours with either BIO-PMs (6×10^{11} or 15×10^{11} BIO PMs ml⁻¹) or 2 μM BIO, ($n = 3$). (D) Relative fold expression of *SP7* in BMSCs incubated for 24 or 96 hours with either BIO-PMs (6×10^{11} or 15×10^{11} BIO PMs ml⁻¹) or 2 μM BIO. Values are normalized against housekeeping gene *GAPDH* and are expressed as fold difference compared to untreated cells. All the data is presented as mean \pm SD and analyzed with two-way ANOVA, **** $p < 0.0001$, *** $p < 0.001$.

with BIO-PMs at a concentration of 15×10^{11} PMs ml⁻¹ resulted in a prolonged up-regulation of *RUNX2*, as evidenced by the gene expression 4 days post exposure (2.3 ± 0.96 fold increase compared to control, $p < 0.05$) (Figure 6, C). Similar to free BIO incubation of BMSCs with BIO-PMs also promoted the up-regulation of *SP7* (also known as Osterix), which is another key gene involved in the osteogenic commitment (Figure 6, D). Together this data indicates that BIO-PMs activate Wnt signalling in human BMSCs and promote their initial osteogenic commitment.

Discussion

Polymeric nanoparticles have potential for drug delivery where spatiotemporal delivery of a drug is key. Canonical Wnt signalling in bone repair is one such example. In this study, we have demonstrated that; (i) PMs can carry high concentrations of a relatively water-insoluble activator of Wnt signalling, (ii) PMs are taken up by cells important in the bone reparative process, and (iii) that activation of canonical Wnt signalling and osteogenic differentiation can be achieved while avoiding the toxicity that BIO causes when delivered with no carrier.

In cases of severe fractures, a pharmacological treatment aimed to promote bone repair could be beneficial in order to limit

the incidence non-healing fractures. It is estimated that 10% to 50% of all the fractures diagnosed, depending on their anatomical localization, will not heal adequately, resulting in what is defined as ‘non-union’.^{16,40} Currently, bone morphogenetic proteins (BMPs) are the only growth factors approved for aiding fracture healing.⁴¹ However, there are several limitations when using BMPs in clinic, including osteolysis, soft tissue swelling, ectopic bone formation due to the use of supra-physiological doses, and the high cost of the drug.⁴² Wnt could therefore be a more robust and reliable molecular target. Encapsulation of Wnt agonist in a drug delivery system could limit the off-target accumulation and dramatically reduce the doses administered.

Liposomes loaded with Wnt proteins have been shown to be effective in promoting bone repair following local administration,²⁰ and in inducing the osteogenic differentiation of human skeletal stem cell populations.²³ However, liposomes are limited by short half-life *in vivo*⁴⁴ and have a limited ability to retain payloads.² Conversely, PMs are able to protect the payload from degradation in addition to high circulation half-life and low off-site accumulation *in vivo*.^{12,45} PMs core-shell structure allows for accommodation of hydrophilic and hydrophobic payloads simultaneously, including molecules soluble in both phases. BIO is soluble in organic solvents (*i.e.* DMF) and in

water (up to a concentration of 14 mM⁴⁶). Here, PMs were loaded with BIO by incorporating it either in the polymer/DMF solution or in the PBS bath. In the PBS-dissolved preparation the inclusion of BIO led to PM instability with changes in size 14 days post-production. An explanation for this observation is that BIO precipitates out of solution within the PM core causing perturbations to the PM structure and its premature collapse. The final concentration of BIO encapsulated in the two preparations was investigated using absorbance spectroscopy.⁴⁷ This technique has inherent limitations including poor quantitative sensitivity and may underestimate the final concentration of BIO if any of it is in the solid state. Future studies using high performance liquid chromatography will be needed to better characterize BIO encapsulation.

We demonstrated that PMs are internalized by Wnt reporter cells and that the presence of BIO does not affect cellular uptake. Using a luciferase assay we have shown that DMF-dissolved PMs were significantly more active than PBS-dissolved PMs. This may be due to the fact that the 6 carbon atoms present in PCL backbone structure create strong supramolecular hydrophobic interactions between the molecule and the polymer itself when the two are dissolved in the same phase.⁴⁸ Previous work has demonstrated that the solubility of hydrophobic drugs within a PM preparation is determined by the number of hydrogen bonds between payload and polymer, and given a constant concentration of drug, these bonds are directly proportional to the number of PCL monomers present.⁴⁹ This would also explain the high level of association between BIO molecules and PMs demonstrated by dialysis and ultracentrifugation.

Regardless of the mechanism by which BIO was incorporated in PMs, drug release occurs rapidly following uptake, as determined by Wnt reporter cell assays. It can be hypothesized that hydrolytic processes taking place at the interface between PEG and PCL^{50,51} would promote the progressive exposure of BIO molecules to the extra-vesicular environment, which may result in an increased gradient pressure with subsequent release through diffusion.⁵²

A concentration of 15×10^{11} BIO-PMs ml⁻¹ and an extracellular concentration of 2 μ M BIO induced similar levels of Wnt signalling activation in reporter cells, which was approximately ~40% of the maximal activation measured (following incubation with an extracellular concentration of 5 μ M BIO). The relationship between concentration of BIO-PMs used and intensity of Wnt signalling measured was biphasic, similar to that observed with free BIO. However, the two conditions had the opposite effect on cellular viability. High concentrations of free BIO were cytotoxic for the reporter cells, in line with previous observations on several cancer cells.^{36,38,46} In contrast, incubation with BIO-PMs did not induce cellular toxicity indicating that intracellular delivery using PMs avoids the activation of molecular pathways that are switched on when BIO is delivered in its free form, or PMs may mediate a protective action that inhibits BIO cytotoxicity. This may be mediated by the slow release of the payload into the cytoplasm. Pulse-chase experiments suggested that maximal activation of the Wnt pathway following incubation with BIO-PMs is delayed compared to free BIO. It has been demonstrated that intact PEG-PCL nanoparticles are still present intracellularly 24 hours

after their initial cellular internalisation.⁵³ These data suggest that PMs could function as intracellular depot of payloads⁵⁰ and may explain the protective mechanism mediated by PMs. If it is assumed that BIO cytotoxicity is induced by the total inhibition of one of the CDKs,³⁸ it is possible that the high intracellular concentration of free BIO is inhibiting the kinase at any given time, while the slow release from PMs is sufficient to transiently inhibit the kinase, but not enough to prevent its reactivation over time resulting in the absence of cytotoxicity. Furthermore, the depot effect mediated by PMs induces a sustained activation of the Wnt signalling pathway over the course of 48 hours. A limitation of these findings is that the level of activity recorded using the reporter cells is a reflection of the amount of functional luciferase enzyme produced, and the luciferase readout can be significantly affected by a number of factors (i.e. the number of empty-PMs present in solution). In order to overcome these limitations, it would be important to quantify the intracellular concentration of BIO at different time points following incubation with either free BIO or BIO-PMs. For example, in future experiments it would be useful to create isotope-labeled variants of both BIO and PEG-PCL copolymer in order to be able to accurately quantify their concentration within the cells after uptake.

Finally, we investigated the application of BIO-PMs as possible source of controlled Wnt signalling activation for therapeutic purposes. First, we demonstrated that BIO-PMs are internalized by BMSCs inducing increased expression of *AXIN2*, which demonstrates the activation of the Wnt pathway. The results obtained with BMSCs corroborated what observed in the reporter cells, whereby BIO-PMs induce the maximal activation of the Wnt pathway after a 48 hour incubation, reinforcing the hypothesis that PMs function as intracellular depot for BIO. Secondly, we demonstrated the increased relative expression of both *RUNX2* and *SP7* following incubation with BIO-PMs. These genes are involved in the early osteogenic differentiation of BMSCs.⁵⁴ This is in agreement with previous studies.^{55,56} Very recently, Low and colleagues demonstrated that micelles loaded with BIO and tethered with a bone-targeting peptide were able to increase both bone mineral density and bone volume in mice models of bone fracture.⁵⁷ Future studies will address the functionality of BIO-loaded PMs in augmenting bone repair following fracture. Nevertheless, it was demonstrated that PMs could be loaded with BIO and induce significant activation of the Wnt signalling pathway following incubation with either reporter cells or BMSCs. There has not been previous research demonstrating the encapsulation of a GSK-3 β inhibitor in PMs, making the results here especially novel.

In summary, the results presented demonstrate that PMs loaded with BIO can induce the activation of the Wnt signalling pathway. This encapsulation of a small molecule into PMs results in reduced cytotoxicity and in sustained Wnt signalling activation that promotes the early osteogenic differentiation of human stem cells. In view of the continuous advances in polymer chemistry and nanoparticle formulations,⁵⁸ we demonstrated that “basic” PEG-PCL PMs incorporating a commercially available small molecule, may be a simple good candidate for a therapeutic approach focused on promoting bone regeneration following injury.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.nano.2018.02.014>.

References

- Chan JM, Zhang L, Tong R, Ghosh D, Gao W, Liao G, et al. Spatio-temporal controlled delivery of nanoparticles to injured vasculature; 2010 <https://doi.org/10.1073/pnas.0914585107>.
- Discher BM, Won YY, Ege DS, Lee JC, Bates FS, Discher DE, et al. Polymersomes: tough vesicles made from diblock copolymers. *Science* 1999;**284**:1143-6.
- Lomas H, Du J, Canton I, Madsen J, Warren N, Armes SP, et al. Efficient encapsulation of plasmid DNA in pH-sensitive PMPC-PDPA polymersomes: study of the effect of PDPA block length on copolymer-DNA binding affinity. *Macromol Biosci* 2010;**10**:513-30, <https://doi.org/10.1002/mabi.201000083>.
- Qin S, Geng Y, Discher DE, Yang S. Temperature-controlled assembly and release from polymer vesicles of poly(ethylene oxide)-block-poly(N-isopropylacrylamide). *Adv Mater* 2006;**18**:2905-9, <https://doi.org/10.1002/adma.200601019>.
- Cabane E, Malinova V, Meier W. Synthesis of photocleavable amphiphilic block copolymers: toward the design of photosensitive nanocarriers. *Macromol Chem Phys* 2010;**211**:1847-56, <https://doi.org/10.1002/macp.201000151>.
- Photos PJ, Bacakova L, Discher B, Bates FS, Discher DE. Polymer vesicles in vivo: correlations with PEG molecular weight. *J Control Release* 2003;**90**:323-34, [https://doi.org/10.1016/S0168-3659\(03\)00201-3](https://doi.org/10.1016/S0168-3659(03)00201-3).
- Xin H, Jiang X, Gu J, Sha X, Chen L, Law K, et al. Angiogenin-conjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. *Biomaterials* 2011;**32**:4293-305, <https://doi.org/10.1016/j.biomaterials.2011.02.044>.
- Tian X, Nyberg S, Sharp PS, Madsen J, Daneshpour N, Armes SP, et al. LRP-1-mediated intracellular antibody delivery to the central nervous system. *Sci Rep* 2015;**5**:11990, <https://doi.org/10.1038/srep11990>.
- Guan L, Rizzello L, Battaglia G. Polymersomes and their applications in cancer delivery and therapy. *Nanomedicine (Lond)* 2015;**10**:2757-80, <https://doi.org/10.2217/nnm.15.110>.
- Nahire R, Haldar MK, Paul S, Ambre AH, Meghni V, Layek B, et al. Multifunctional polymersomes for cytosolic delivery of gemcitabine and doxorubicin to cancer cells. *Biomaterials* 2014;**35**:6482-97, <https://doi.org/10.1016/j.biomaterials.2014.04.026>.
- Petersen MA, Hillmyer MA, Kokkoli E. Bioresorbable polymersomes for targeted delivery of cisplatin. *Bioconjug Chem* 2013;**24**:533-43, <https://doi.org/10.1021/bc3003259>.
- Simón-Gracia L, Hunt H, Scodeller PD, Gaitzsch J, Braun GB, Willmore A-MA, et al. Paclitaxel-loaded polymersomes for enhanced intraperitoneal chemotherapy. *Mol Cancer Ther* 2016;**15**:670-9.
- Rameez S, Alostia H, Palmer AF. Biocompatible and biodegradable polymersome encapsulated hemoglobin: a potential oxygen carrier. *Bioconjug Chem* 2008;**19**:1025-32, <https://doi.org/10.1021/bc700465v>.
- Wayakanon K, Thornhill MH, Douglas CWI, Lewis AL, Warren NJ, Pinnock A, et al. Polymersome-mediated intracellular delivery of antibiotics to treat *Porphyromonas gingivalis*-infected oral epithelial cells. *FASEB J* 2013;**27**:4455-65, <https://doi.org/10.1096/fj.12-225219>.
- Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. *Nat Med* 2013;**19**:179-92, <https://doi.org/10.1038/nm.3074>.
- Lack WD, Starman JS, Seymour R, Bosse M, Karunakar M, Sims S, et al. Any cortical bridging predicts healing of tibial shaft fractures. *J Bone Joint Surg Am* 2014;**96**:1066-72, <https://doi.org/10.2106/JBJS.M.00385>.
- Brandi ML. Drugs for bone healing. *Expert Opin Investig Drugs* 2012;**21**:1169-76, <https://doi.org/10.1517/13543784.2012.696610>.
- McClung MR. Emerging therapies for osteoporosis. *Endocrinol Metab* 2015;**30**:429, <https://doi.org/10.3803/EnM.2015.30.4.429>.
- Chen Y, Whetstone HC, Lin AC, Nadesan P, Wei Q, Poon R, et al. Beta-catenin signaling plays a disparate role in different phases of fracture repair: Implications for therapy to improve bone healing. *PLoS Med* 2007;**4**:1216-29, <https://doi.org/10.1371/journal.pmed.0040249>.
- Minear S, Leucht P, Jiang J, Liu B, Zeng A, Fuerer C, et al. Wnt proteins promote bone regeneration. *Sci Transl Med* 2010;**2**:29ra30, <https://doi.org/10.1126/scitranslmed.3000231>.
- Janeczka AA, Tare RS, Scarpa E, Moreno-Jimenez I, Rowland CA, Jenner D, et al. Transient canonical wnt stimulation enriches human bone marrow mononuclear cell isolates for osteoprogenitors. *Stem Cells* 2016;**34**:418-30, <https://doi.org/10.1002/stem.2241>.
- Popelut A, Rooker SM, Leucht P, Medio M, Brunski JB, Helms JA. The acceleration of implant osseointegration by liposomal Wnt3a. *Biomaterials* 2010;**31**:9173-81, <https://doi.org/10.1016/j.biomaterials.2010.08.045>.
- Janeczka AA, Scarpa E, Horrocks MH, Tare RS, Rowland CA, Jenner D, et al. PEGylated liposomes associate with Wnt3A protein and expand putative stem cells in human bone marrow populations. *Nanomedicine* 2017;**12**:845-63, <https://doi.org/10.2217/nmm-2016-0386>.
- Li C, Ominsky MS, Tan H-L, Barrero M, Niu Q-T, Asuncion FJ, et al. Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene. *Bone* 2011;**49**:1178-85, <https://doi.org/10.1016/j.bone.2011.08.012>.
- Marsell R, Sisask G, Nilsson Y, Sundgren-Andersson AK, Andersson U, Larsson S, et al. GSK-3 inhibition by an orally active small molecule increases bone mass in rats. *Bone* 2012;**50**:619-27, <https://doi.org/10.1016/j.bone.2011.11.007>.
- Gambardella A, Nagaraju CK, O'Shea PJ, Mohanty ST, Kottam L, Pilling J, et al. Glycogen synthase kinase-3alpha/beta inhibition promotes in vivo amplification of endogenous mesenchymal progenitors with osteogenic and adipogenic potential and their differentiation to the osteogenic lineage. *J Bone Miner Res* 2011;**26**:811-21, <https://doi.org/10.1002/jbmr.266>.
- Sisask G, Marsell R, Sundgren-Andersson A, Larsson S, Nilsson O, Ljunggren O, et al. Rats treated with AZD2858, a GSK3 inhibitor, heal fractures rapidly without endochondral bone formation. *Bone* 2013;**54**:126-32, <https://doi.org/10.1016/j.bone.2013.01.019>.
- Gunn WG, Krause U, Lee N, Gregory CA. Pharmaceutical inhibition of glycogen synthetase kinase-3beta reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model. *Blood* 2011;**117**:1641-51, <https://doi.org/10.1182/blood-2010-09-308171>.
- Neves VCM, Babb R, Chandrasekaran D, Sharpe PT, Goldberg M, Kulkarni AB, et al. Promotion of natural tooth repair by small molecule GSK3 antagonists. *Sci Rep* 2017;**7**:39654, <https://doi.org/10.1038/srep39654>.
- Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? *J Biol Chem* 2001;**276**:251-60, <https://doi.org/10.1074/jbc.M002466200>.
- Scarpa E, Bailey JL, Janeczka AA, Stumpf PS, Johnston AH, Oreffo ROC, et al. Quantification of intracellular payload release from polymersome nanoparticles. *Sci Rep* 2016;**6**:29460, <https://doi.org/10.1038/srep29460>.
- Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. *Nat Med* 2004;**10**:55-63, <https://doi.org/10.1038/nm979>.
- Ying Q-L, Wray J, Nichols J, Batlle-Morera L, Doble B, Woodgett J, et al. The ground state of embryonic stem cell self-renewal. *Nature* 2008;**453**:519-23, <https://doi.org/10.1038/nature06968>.
- Gaboriaud-Kolar N, Vougioukianopoulou K, Skaltsounis A-L. Indirubin derivatives: a patent review (2010 – present). *Expert Opin Ther Pat* 2015;**25**:583-93, <https://doi.org/10.1517/13543776.2015.1019865>.

37. Zhen Y, Sørensen V, Jin Y, Suo Z, Więdołcha A. Indirubin-3'-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MAPK. *Oncogene* 2007;**26**:6372-85, <https://doi.org/10.1038/sj.onc.1210473>.
38. Liu L, Nam S, Tian Y, Yang F, Wu J, Wang Y, et al. 6-Bromoindirubin-3'-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells. *Cancer Res* 2011;**71**:3972-9, <https://doi.org/10.1158/0008-5472.CAN-10-3852>.
39. Arioka M, Takahashi-Yanaga F, Sasaki M, Yoshihara T, Morimoto S, Takashima A, et al. Acceleration of bone development and regeneration through the Wnt/beta-catenin signaling pathway in mice heterozygously deficient for GSK-3beta. *Biochem Biophys Res Commun* 2013;**440**:677-82, <https://doi.org/10.1016/j.bbrc.2013.09.126>.
40. Zimmermann G, Wagner C, Schmeckenbecher K, Wentzensen A, Moghaddam A. Treatment of tibial shaft non-unions: bone morphogenetic proteins versus autologous bone graft. *Injury* 2009;**40**(Suppl 3):S50-3, [https://doi.org/10.1016/s0020-1383\(09\)70012-9](https://doi.org/10.1016/s0020-1383(09)70012-9).
41. Mehta M, Schmidt-Bleek K, Duda GN, Mooney DJ. Biomaterial delivery of morphogens to mimic the natural healing cascade in bone. *Adv Drug Deliv Rev* 2012;**64**:1257-76, <https://doi.org/10.1016/j.addr.2012.05.006>.
42. Lissenberg-Thunnissen SN, de Gorter DJJ, Sier CFM, Schipper IB. Use and efficacy of bone morphogenetic proteins in fracture healing. *Int Orthop* 2011;**35**:1271-80, <https://doi.org/10.1007/s00264-011-1301-z>.
44. Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: theory to practice. *Pharmacol Rev* 2001;**53**:283-318.
45. Ahmed F, Pakunlu RI, Brannan A, Bates F, Minko T, Discher DE. Biodegradable polymersomes loaded with both paclitaxel and doxorubicin permeate and shrink tumors, inducing apoptosis in proportion to accumulated drug. *J Control Release* 2006;**116**:150-8, <https://doi.org/10.1016/j.jconrel.2006.07.012>.
46. Vougiannopoulos K, Ferandin Y, Bettayeb K, Myrianthopoulos V, Lozach O, Fan Y, et al. Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period. *J Med Chem* 2008;**51**:6421-31, <https://doi.org/10.1021/jm800648y>.
47. Buckiova D, Ranjan S, Newman TA, Johnston AH, Sood R, Kinnunen PK, et al. Minimally invasive drug delivery to the cochlea through application of nanoparticles to the round window membrane. *Nanomedicine (Lond)* 2012;**7**:1339-54, <https://doi.org/10.2217/nmm.12.5>.
48. Shuai X, Ai H, Nasongkla N, Kim S, Gao J. Micellar carriers based on block copolymers of poly(ϵ -caprolactone) and poly(ethylene glycol) for doxorubicin delivery. *J Control Release* 2004;**98**:415-26, <https://doi.org/10.1016/j.jconrel.2004.06.003>.
49. Patel SK, Lavasanifar A, Choi P. Molecular dynamics study of the encapsulation capability of a PCL-PEO based block copolymer for hydrophobic drugs with different spatial distributions of hydrogen bond donors and acceptors. *Biomaterials* 2010;**31**:1780-6, <https://doi.org/10.1016/j.biomaterials.2009.11.060>.
50. Ahmed F, Discher DE. Self-porating polymersomes of PEG-PLA and PEG-PCL: hydrolysis-triggered controlled release vesicles. *J Control Release* 2004;**96**:37-53, <https://doi.org/10.1016/j.jconrel.2003.12.021>.
51. Ultra NS, Nair P, Discher DE. From stealthy polymersomes and filomicelles to "self" Peptide-nanoparticles for cancer therapy. *Annu Rev Chem Biomol Eng* 2014;**5**:281-99, <https://doi.org/10.1146/annurev-chembioeng-060713-040447>.
52. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MNVR. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. *Pharm Sci* 2009;**37**:223-30, <https://doi.org/10.1016/j.ejps.2009.02.019>.
53. Chernenko T, Matthäus C, Milane L, Quintero L, Amiji M, Diem M. Label-free Raman spectral imaging of intracellular delivery and degradation of polymeric nanoparticle systems. *ACS Nano* 2009;**3**:3552-9, <https://doi.org/10.1021/nn9010973>.
54. Bruderer M, Richards RG, Alini M, Stoddart MJ. Role and regulation of RUNX2 in osteogenesis. *Eur Cell Mater* 2014;**28**:269-86.
55. Krause U, Harris S, Green A, Ylostalo J, Zeitouni S, Lee N, et al. Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy. *Proc Natl Acad Sci* 2010;**107**:4147-52, <https://doi.org/10.1073/pnas.0914360107>.
56. Zahoor M, Cha PH, Choi KY. Indirubin-3'-oxime, an activator of Wnt/beta-catenin signaling, enhances osteogenic commitment of ST2 cells and restores bone loss in high-fat diet-induced obese male mice. *Bone* 2014;**65**:60-8, <https://doi.org/10.1016/j.bone.2014.05.003>.
57. Low SA, Galliford CV, Jones-Hall YL, Roy J, Yang J, Low PS, et al. Healing efficacy of fracture-targeted GSK3 β inhibitor-loaded micelles for improved fracture repair. *Nanomedicine* 2017;**12**:185-93, <https://doi.org/10.2217/nmm-2016-0340>.
58. Anchordoquy TJ, Simberg D. *Watching the gorilla and questioning delivery dogma*, 262; 2017, <https://doi.org/10.1016/j.jconrel.2017.07.021>.